Belite Bio, Inc (BLTE) News
Follow Belite Bio, Inc (BLTE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 21 public stories across 15 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Belite Bio announces uplisting to Nasdaq Global Select Market
EQUITY | Oct 19, 2026, 10:00 AM UTC
L
Belite Bio submits marketing applications for tinlarebant
Belite Bio announced multi-market submissions of marketing authorization applications via the Access Consortium pathway for tinlarebant to treat Stargardt disease type 1.
REGULATION | Oct 14, 2026, 08:00 PM UTC
L
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc NASDAQ:BLTE (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal
NEWS | Sep 29, 2026, 12:08 AM UTC
L
Mizuho keeps Belite Bio at outperform; raises target to $234
Mizuho maintained Belite Bio at outperform and raised its price target to $234.00 per share from $220.00, according to Benzinga via TradingView News.
EQUITY | Sep 09, 2026, 02:41 PM UTC
L
HC Wainwright raises Belite Bio price target to $245
HC Wainwright & Co. raised its price target for Belite Bio to $245.00 per share from $214.00, according to Benzinga (via TradingView News).
EQUITY | Sep 08, 2026, 03:30 PM UTC
M
Belite Bio submits Japan NDA for tinlarebant under Sakigake
Belite Bio announced submission of a new drug application to Japan’s Ministry of Health, Labour and Welfare for tinlarebant to treat Stargardt disease type 1 under Sakigake designation.
EQUITY | Sep 08, 2026, 10:00 AM UTC
L
Belite Bio shares jump on Canaccord Buy initiation for tinlarebant
Canaccord Genuity initiated Belite Bio with a Buy rating and $303 price forecast, citing upside tied to FDA-accepted tinlarebant marketing application. Shares were up 9.63% to $187.56.
EARNINGS | Sep 04, 2026, 05:41 PM UTC
L
Belite Bio initiated at Buy by Canaccord Genuity
Canaccord Genuity initiated coverage on Belite Bio with a Buy rating and set a $303.00 per-share price target.
EQUITY | Sep 04, 2026, 12:16 PM UTC
L
Belite Bio to participate in four upcoming investor conferences
Belite Bio, a clinical-stage drug development company focused on degenerative retinal diseases, announced participation in four upcoming investor conferences.
EQUITY | Sep 01, 2026, 12:07 PM UTC
L
BLTE - Belite Bio to Participate in Four Upcoming Investor Conferences
BLTE - Belite Bio to Participate in Four Upcoming Investor Conferences
EQUITY | Sep 01, 2026, 12:01 PM UTC
L
BLTE - Belite Bio to Host Virtual Commercial Day on September 2, 2026
BLTE - Belite Bio to Host Virtual Commercial Day on September 2, 2026
EQUITY | Aug 24, 2026, 08:00 PM UTC
L
Belite Bio announces oral presentations at two medical conferences
Belite Bio said it will give oral presentations at two upcoming medical conferences.
EQUITY | Aug 21, 2026, 12:00 PM UTC
L
Belite Bio reports Q2 loss, FDA accepts tinlarebant NDA
Belite Bio said the FDA accepted its new drug application for tinlarebant with priority review and set a PDUFA date of February 12, 2027, while Q2 GAAP net loss widened to $28.4 million from $16.3 million.
EARNINGS | Aug 13, 2026, 08:53 PM UTC
L
Belite Bio (BLTE) reports unaudited Q2 2026 results and corporate update
Belite Bio (BLTE) reports unaudited second quarter 2026 financial results and provides a corporate update, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 01:45 AM UTC
L
BLTE Price Target Raised
H.C. Wainwright raises BLTE price target to $214 from $200
EQUITY | Aug 12, 2026, 10:47 AM UTC
L
Belite Bio Announces FDA Acceptance And Priority Review Of Tinlarebant NDA For Stargardt Disease Type 1, With PDUFA Date Of February 12, 202
Belite Bio Announces FDA Acceptance And Priority Review Of Tinlarebant NDA For Stargardt Disease Type 1, With PDUFA Date Of February 12, 2027
REGULATION | Aug 11, 2026, 08:04 PM UTC
H
BLTE: FDA Accepts NDA for Stargardt Disease Treatment
Belite Bio's NDA for Tinlarebant is accepted by the FDA for priority review
REGULATION | Aug 11, 2026, 08:01 PM UTC
L
BLTE - Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
BLTE - Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
EARNINGS | Aug 06, 2026, 12:02 PM UTC
L
BLTE Belite Bio announces oral presentation at the asrs annual meeting featuring additional positive secondary endpoint data from the phase
BLTE Belite Bio announces oral presentation at the asrs annual meeting featuring additional positive secondary endpoint data from the phase 3 trial of tinlarebant in stargardt disease type 1 Belite Bio - tinlarebant well
EQUITY | Jul 20, 2026, 12:02 PM UTC
L
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -
EQUITY | Jul 06, 2026, 12:01 PM UTC
L
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -
EQUITY | Jul 06, 2026, 11:01 AM UTC